MedTrace Logo

Neuroprotective Role of Erythropoietin in Perinatal Asphyxia

NCT02002039 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2016-10-14

No results posted yet for this study

Summary

Whether Erythropoietin improves the neurological outcomes of neonates with perinatal asphyxia.

Conditions

  • Perinatal Asphyxia

Interventions

DRUG

Erythropoietin

500 units /kg /day every other day for 5 doses

Sponsors & Collaborators

  • Sheri Kashmir Institute of Medical Sciences

    lead OTHER

Principal Investigators

  • Feroz Shaheen, MD · SKIMS

  • Prof. WAjid Ali · SKIMS

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Max Age
6 Hours
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02002039 on ClinicalTrials.gov